Surgery Partners (NASDAQ:SGRY) Lowered to Hold Rating by Zacks Research

Zacks Research cut shares of Surgery Partners (NASDAQ:SGRY) from a strong-buy rating to a hold rating in a research report released on Monday,Zacks.com reports.

A number of other analysts have also recently commented on SGRY. Benchmark restated a “buy” rating on shares of Surgery Partners in a research report on Tuesday. Raymond James Financial set a $18.00 target price on Surgery Partners in a report on Tuesday. Cantor Fitzgerald restated an “overweight” rating and issued a $18.00 price target on shares of Surgery Partners in a report on Tuesday. Jefferies Financial Group reaffirmed a “buy” rating and set a $17.00 price target on shares of Surgery Partners in a research report on Wednesday, May 6th. Finally, Royal Bank Of Canada cut their price objective on Surgery Partners from $20.00 to $19.00 and set an “outperform” rating on the stock in a report on Tuesday. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $19.45.

Surgery Partners Stock Down 6.0%

Shares of NASDAQ:SGRY opened at $15.00 on Monday. Surgery Partners has a 52 week low of $11.41 and a 52 week high of $24.10. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.69 and a current ratio of 1.86. The company has a market capitalization of $1.96 billion, a PE ratio of -21.43, a PEG ratio of 4.77 and a beta of 1.91. The company has a 50 day moving average price of $15.51 and a two-hundred day moving average price of $14.43.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Monday, August 10th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.06 by $0.04. The company had revenue of $848.90 million for the quarter, compared to analyst estimates of $830.03 million. Surgery Partners had a negative net margin of 2.63% and a positive return on equity of 0.87%. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. During the same period last year, the business posted $0.17 earnings per share. Analysts forecast that Surgery Partners will post 0.25 earnings per share for the current year.

Institutional Investors Weigh In On Surgery Partners

Several institutional investors have recently added to or reduced their stakes in SGRY. Janus Henderson Group PLC increased its holdings in Surgery Partners by 3.8% during the 4th quarter. Janus Henderson Group PLC now owns 13,537,984 shares of the company’s stock worth $209,162,000 after purchasing an additional 501,401 shares in the last quarter. Pentwater Capital Management LP lifted its holdings in shares of Surgery Partners by 66.9% in the third quarter. Pentwater Capital Management LP now owns 11,681,000 shares of the company’s stock valued at $252,777,000 after purchasing an additional 4,681,000 shares in the last quarter. UBS Group AG lifted its holdings in shares of Surgery Partners by 111.4% in the fourth quarter. UBS Group AG now owns 7,803,974 shares of the company’s stock valued at $120,571,000 after purchasing an additional 4,113,052 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Surgery Partners in the second quarter valued at about $104,857,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of Surgery Partners by 7.9% during the first quarter. Dimensional Fund Advisors LP now owns 5,296,411 shares of the company’s stock worth $63,131,000 after buying an additional 389,831 shares during the period.

Trending Headlines about Surgery Partners

Here are the key news stories impacting Surgery Partners this week:

• Positive Sentiment: Q2 results beat expectations: Adjusted earnings were $0.10 per share versus the $0.06 consensus estimate, while revenue of $848.9 million exceeded the $830.0 million forecast. Revenue increased 2.7% year over year, and same-facility revenue rose 5.0%. Surgery Partners Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Full-year guidance was reaffirmed: Surgery Partners continues to expect 2026 revenue of $3.35 billion to $3.45 billion and adjusted EBITDA of at least $530 million, excluding the pending Idaho Falls divestiture. Management said the transaction should improve cash conversion and support deleveraging. Surgery Partners Announces Second Quarter Results
• Positive Sentiment: Analyst support remains favorable: Cantor Fitzgerald reaffirmed its “overweight” rating and set an $18 price target. A separate brokerage consensus target was reported at $21.60, implying substantial potential upside from recent trading levels. Cantor Fitzgerald Reiterates Overweight Rating
• Neutral Sentiment: Broader healthcare stocks could benefit if weak employment data increases expectations for Federal Reserve interest-rate cuts, although this is a sector-wide factor rather than a Surgery Partners-specific catalyst. Likely ETF and Stock Winners From July Jobs Report
• Negative Sentiment: Profitability and cash generation weakened: Q2 net loss attributable to Surgery Partners widened to $15.0 million from $2.5 million a year earlier. Adjusted EBITDA declined to $125.2 million from $129.0 million, while operating cash flow fell to $59.3 million from $81.3 million. Net debt remained elevated at approximately 4.4 times EBITDA. Surgery Partners Reports Second Quarter Results

About Surgery Partners

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.